Patrik Jeanmonod - 28 Feb 2022 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
Chief Financial Officer
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Patrik Jeanmonod
Issuer symbol
CTKB
Transactions as of
28 Feb 2022
Net transactions value
$0
Form type
4
Filing time
02 Mar 2022, 16:54:05 UTC
Previous filing
22 Jul 2021
Next filing
20 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTKB Stock Option (Right to Buy) Award $0 +42,310 $0.000000 42,310 28 Feb 2022 Common Stock 42,310 $13.64 Direct F1
transaction CTKB Restricted Stock Units Award $0 +28,042 $0.000000 28,042 28 Feb 2022 Common Stock 28,042 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option vest monthly over four years from the vesting commencement date of January 1, 2022. The option becomes fully vested on January 1, 2026.
F2 Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F3 The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.